We are a group of professionals with diverse backgrounds from pharmaceutical development and marketing through pharmacology and toxicology to healthcare management, corporate finance, and asset management, who have come together to create Auxilius Pharma with the purpose of addressing the unmet clinical needs of many patients.

We are developing a unique portfolio of value-added reformulated product candidates by utilizing our expertise and technological advancements in drug formulation and manufacturing.

Our development approach makes use of the 505(b)(2) regulatory pathway in the United States. This pathway has been created for pharmaceutics for which the safety and efficacy have previously been demonstrated. This targeted approach can considerably cut the amount of clinical work necessary to get a product to market, shorten the development cycle, and lower costs and risks.